biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > New Questions

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 09, 2023 2:39pm

219 Views

Post# 35488967

RE:New Questions

"Did the Janssen agreement expire on January 31, 2023, as called for in their agreement with Bioasis? Note that the expiration, January 31, is convenient in that the date is a day or two after Bioasis released their Q3 filings, meaning that shareholders then wouldn’t know anything about it before the February AGM and until the annual report comes out at the end of June, about 3 weeks from now."

Midatech's CEO hyped BTI's xB3 partnerships and the potential milestones. etc. I believe there could be a path out of BTI's current situation. I believe the Chiesi deal is still active. With Fabry approved Chiesi has a strategic foothold in LSDs and the brain is a strategic area for LSDs. The Neuramedy deal could be monitized. I believe at the AGM Rathjen said that the option agreement with J&J has been extended, expanded, and a small milestone was paid. We are now about 4 1/2 months past the original Jan. 31, 2023 expiry date for the J&J option. We could be very close to options exercise. J&J needs big markets to move the financial needle. The exercise of a multi-product licensing deal with J&J could be meaningful in terms of upfront money and validation for xB3. The J&J deal could also be monitized with XOMA as the Prothena and Chiesi deals were.

Gildas Deniau, who is a Senior Scientist at Janssen in its Peptide Center of Excellence, 'liked' a BTI Linkedin post about two months ago. The BTI post said "Our proprietary xB3 platform enables the delivery of therapeutics into the brain It transports molecules across the blood-brain barrier & into the brain, where they can effectively treat neurological disorders." Nice to have that affirmed by a Senior Scientist at J&J at this time. That is a broad statement.

Here's the Senior Scientists profile: